Infection Control and Disease Surveillance in Africa

By Crystal Lubbe

December 10, 2024

The topic of National borders as a critical frontline in containing deadly infections is increasingly significant for public health initiatives. The Africa CDC plays a crucial role in addressing infection prevention and control measures linked to these borders. Their approach emphasises the necessity of robust systems and collaborations that allow for effective management of health threats that cross national boundaries.

Infection Prevention and Control (IPC) Legal Framework

The Africa CDC has developed a comprehensive IPC Legal Framework aimed at strengthening infection prevention and control measures across African Union Member States. This framework incorporates six critical areas:
– Establishing national IPC programs
– Developing evidence-based guidance
– Training and educating personnel
– Conducting surveillance for healthcare-associated infections (HAIs)
– Developing systems to monitor compliance with laws
– Mandating specific staffing and infrastructure changes in hospitals.

Implementation and Support

The Africa CDC is actively assisting Member States in implementing this IPC Legal Framework through financial, technical, and collaborative support. Workshops and joint efforts with countries like Cameroon, Liberia, Malawi, and Nigeria have been conducted to review and enhance existing IPC programs and legal instruments.

Disease Surveillance and Health Security

In collaboration with the World Health Organization (WHO) and other partners, the Africa CDC has launched initiatives to strengthen disease surveillance and health security across Africa. This includes the Health Security Partnership designed to enhance integrated disease surveillance, event-based surveillance, genomic surveillance, and epidemic intelligence. Such partnerships are invaluable for swiftly detecting and addressing health security threats, especially since national borders serve as a critical frontline in containing deadly infections.

Cross-Border Disease Control

National borders are crucial in containing infections, making RISLNET vital. It harmonises labs, integrates surveillance, and boosts cross-border collaboration to combat regional health challenges.

Multi-Sectoral Collaboration

The Africa CDC promotes a multi-sectoral approach to align IPC measures with regional and international standards. This collaborative effort is crucial for effective implementation and fostering a healthier and safer environment across the continent.

In summary, the Africa CDC’s efforts in infection prevention and control, disease surveillance, and health security therefore, illustrate the vital role of National borders as a critical frontline in containing deadly infections. Their documented initiatives highlight the importance of robust legal frameworks, cross-border collaboration, and multi-sectoral approaches to effectively combat health threats.

Reference url

Recent Posts

CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a